drugset
Drugs / [11C]DPA-713
last change Apr 2018 re-read 3 minutes ago

[11C]DPA-713

also known as carbon-11 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo\[1,5-a\]pyrimidine-3-acetamide, (\[11C\]DPA)-713

Diagnostic / imaging agent

Investigated by
Johns Hopkins University

Trials 1

today NCT03257592 · Ph 1
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03257592 Aug 2010 → Apr 2018 bipolar disorder, schizophrenia Johns Hopkins University Terminated No outcome recorded Stop: Business

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as [11C]DPA-713 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03257592 ↗
Known as carbon-11 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo\[1,5-a\]pyrimidine-3-acetamide, (\[11C\]DPA)-713 “Here, the investigators aim to use PET-based neuroimaging with carbon-11 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo\[1,5-a\]pyrimidine-3-acetamide, (\[11C\]DPA)-713...” NCT03257592 ↗
Modality Diagnostic / imaging agent “PET-based neuroimaging” NCT03257592 ↗